Aeterna Zentaris Inc
TSX:AEZS

Watchlist Manager
Aeterna Zentaris Inc Logo
Aeterna Zentaris Inc
TSX:AEZS
Watchlist
Price: 5.1 CAD -0.97% Market Closed
Market Cap: 18.9m CAD

Aeterna Zentaris Inc
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Aeterna Zentaris Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Aeterna Zentaris Inc
TSX:AEZS
Net Income (Common)
-$18.1m
CAGR 3-Years
-35%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Income (Common)
$2.3B
CAGR 3-Years
-44%
CAGR 5-Years
-20%
CAGR 10-Years
-2%
Gilead Sciences Inc
NASDAQ:GILD
Net Income (Common)
$8.1B
CAGR 3-Years
34%
CAGR 5-Years
45%
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Net Income (Common)
$7B
CAGR 3-Years
1%
CAGR 5-Years
-1%
CAGR 10-Years
1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Income (Common)
$3.7B
CAGR 3-Years
4%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Income (Common)
$4.6B
CAGR 3-Years
-5%
CAGR 5-Years
8%
CAGR 10-Years
23%
No Stocks Found

Aeterna Zentaris Inc
Glance View

Market Cap
18.9m CAD
Industry
Biotechnology

Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The company is headquartered in Montreal, Quebec and currently employs 17 full-time employees. The firm's lead product, Macrilen (macimorelin), is an oral test indicated for the diagnosis of patients with adult growth hormone deficiency (AGHD). Macrilen (macimorelin) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor (GHSR-1a) and has uses in both endocrinology and oncology indications. The firm is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). The company is also developing oral prophylactic bacterial vaccines against each of SARS-CoV-2, the virus that causes COVID-19, and Chlamydia Trachomatis. The firm focuses on the commercialization of macimorelin in Asia and the rest of the world.

AEZS Intrinsic Value
Not Available

See Also

What is Aeterna Zentaris Inc's Net Income (Common)?
Net Income (Common)
-18.1m USD

Based on the financial report for Mar 31, 2024, Aeterna Zentaris Inc's Net Income (Common) amounts to -18.1m USD.

What is Aeterna Zentaris Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-4%

Over the last year, the Net Income (Common) growth was 26%. The average annual Net Income (Common) growth rates for Aeterna Zentaris Inc have been -35% over the past three years , -4% over the past five years .

Back to Top